Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | AMGN Amgen | ABT Abbott Laboratories |
|---|---|---|
| Price | $379.78 +1.1% | $102.23 +0.2% |
| StockIQ Score | 52C- Moderate Risk: High | 51C- Moderate Risk: Medium |
| Technical | 29F | 23F |
| Fundamental | 69B- | 72B |
| Growth | 62C+ | 45D+ |
| Fair Value | 38F | 38F |
| News | 98A+ | 98A+ |
| Quality | 42D | 63C+ |
| Risk | 44D | 54C- |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Amgen outperforms Abbott Laboratories in technical (73 vs. 50) and growth (62 vs. 45) scores, showing stronger market trends and expansion potential. Abbott leads in fundamental analysis (72 vs. 69), indicating better core financial health. Both share the same valuation score of 38, while Amgen’s higher investor score (61 vs. 56) suggests greater market confidence.